Healthcare / Drug Manufacturers - Specialty & GenericBSE
$11.24
-0.01 (-0.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-197.4M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
15.4x
↓EV/EBITDA
8.6x
↓ROE
9.7%
↑Gross Margin
28.6%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.0%
FCF CAGR
—
FCF margin
-14.4%
FCF / Net income
-1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.38B · net income $181.2M · FCF $-197.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.38B | $1.38B | $791.0M | $649.6M | $611.8M |
| Net Income | $181.2M | $181.2M | $131.8M | $49.2M | $39.2M |
| EBITDA | $271.5M | $271.5M | $219.4M | $86.5M | $67.6M |
| EPS | 0.78 | 0.78 | 0.61 | 0.32 | 0.31 |
| Gross Margin | 28.6% | 28.6% | 36.7% | 37.1% | 36.8% |
| Operating Margin | 10.7% | 10.7% | 18.5% | 5.8% | 8.3% |
| Net Margin | 13.2% | 13.2% | 16.7% | 7.6% | 6.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.11 | 0.22 | 0.23 |
| Cash Flow | |||||
| Free Cash Flow | $-197.4M | $-197.4M | $-466.9M | $-161.1M | $103.1M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 7.7% | 6.1% | 9.0% |
| Valuation | |||||
| P/E | 15.40 | 15.40 | 28.90 | 18.90 | 26.36 |
| EV/EBITDA | 8.57 | 8.57 | 15.47 | 10.55 | 15.69 |
| P/B | 1.39 | 1.39 | 2.23 | 1.10 | 2.36 |
| Growth & Yield | |||||
| Revenue Growth | 73.9% | 73.9% | 21.8% | 6.2% | — |
| EPS Growth | 28.8% | 28.8% | 90.6% | 2.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.4%
EPS terminal req.
$1.00
Spread vs growth
20.4%
5Y implied EPS CAGR
9.0%
EPS terminal req.
$1.21
Spread vs growth
19.7%
10Y implied EPS CAGR
9.5%
EPS terminal req.
$1.94
Spread vs growth
19.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.9%
Start / end P/E
22.8x → 14.4x
EPS bridge
0.61 → 0.78
Residual
-10.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.